Compare MYPS & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MYPS | ICCC |
|---|---|---|
| Founded | 2011 | 1982 |
| Country | United States | United States |
| Employees | 543 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 55.5M | 64.0M |
| IPO Year | N/A | 1995 |
| Metric | MYPS | ICCC |
|---|---|---|
| Price | $0.42 | $8.35 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | ★ 350.5K | 25.9K |
| Earning Date | 05-05-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 53.85 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $26,493,169.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 51.64 |
| 52 Week Low | $0.41 | $4.52 |
| 52 Week High | $1.68 | $8.46 |
| Indicator | MYPS | ICCC |
|---|---|---|
| Relative Strength Index (RSI) | 39.33 | 72.35 |
| Support Level | $0.42 | $5.78 |
| Resistance Level | $0.49 | N/A |
| Average True Range (ATR) | 0.03 | 0.31 |
| MACD | -0.00 | 0.08 |
| Stochastic Oscillator | 12.30 | 95.95 |
PLAYSTUDIOS Inc is engaged in gaming and related business. The Company develops and operates online and mobile social gaming applications (games or game), many of which incorporate a loyalty program offering real world rewards provided by a collection of awards partners. The Companies games are free-to-play and available via the Apple App Store, Google Play Store, Amazon Appstore and Facebook (collectively, platforms or platform operators). The Company creates games based on its own original content as well as third-party licensed brands. The Company generates revenue through the in-game sales of virtual currency and through advertising. The company has one operating segment with one business activity, developing and monetizing social games.
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.